Lytix Biopharma

[drdr]

Har noen en forventning/gjetning om morgendagens pressekonferanse etter ESMO?

[vegar_beider]

Du mener webcasten?
Ordlyden i invitasjonen tilsier at det skal gis enda mer informasjon der enn det som fremkommer ved kun å se på posteren, så om det stemmer så er det jo absolutt en webcast å få med seg.

The webcast is being held to provide further insights and additional information about the preliminary data from the ATLAS-IT-05 study, that is being presented in a poster session at ESMO

Har uansett forventning om at data som presenteres i morgen er up to date og forhåpentligvis inkluderer mange flere en de 7 pasientene som hadde den nødvendige ≥1 post-baseline scan ved siste cut off date som var 24 April.

[TekBot]

Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023

Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Stephane Dalle, the top recruiting investigator of the ATLAS-IT-05 study, will give a poster presentation today at the ESMO 2023 Congress.

ATLAS-IT-05 is a Phase II open label clinical trial with LTX-315 in combination with Keytruda® (pembrolizumab) in stage III-IV melanoma patients refractory to treatment with PD-1 / PD-L1 inhibitors.
…

Vis børsmeldingen

The poster presents early preliminary clinical data from 20 patients (14 patients for efficacy) with advanced melanoma who have failed a checkpoint inhibitor and have a poor prognosis. Most of the enrolled patients have failed on several lines of treatment, including combined checkpoints or BRAF/MEK inhibition. The results are based on an early read out from the study with a median follow-up of 15 weeks.

The combination with LTX-315 and pembrolizumab demonstrates prolonged stabilization in this heavily pre-treated patient population with a disease control rate of 43% and at this early time point showing one patient achieving a partial response. Almost half of the patients are continuing on the trial.
Some patients have shown impressive evidence of significant tumor shrinkage in both injected and non-injected lesions, and LTX-315 was well-tolerated with general mild to moderate treatment related adverse events.

The trial is currently ongoing, and the interim data are considered immature – further details will be shared in a future presentation. The patients are still early in the treatment course, and conclusions drawn from this interim report could change over time.

Dr. Øystein Rekdal, Chief Executive Officer at Lytix Biopharma, commented:
”Even though these data are early, we are encouraged by the promising signs of efficacy seen so far. We are looking forward to seeing the results from the full cohort of patients enrolled in the study, followed over a longer time period. We expect to report top line data from 20 patients in Q1 2024. We are also in the process of submitting an amendment for the initiation of an expansion cohort with up to 20 additional patients.”

---

Details for the poster session are as follows:

• Poster Title: Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: interim results from the ATLAS-IT-05 trial
• Presenter: Stephane Dalle
• Poster Number: 1051P
• Session: Investigational immunotherapy
• Session Date and Time: Monday, October 23, 2023
• Session Location: Hall 8

The poster and webcast presentation are available on Lytix’s website; https://www.lytixbiopharma.com

---

WEBCAST AND Q&A
Øystein Rekdal, Chief Executive Officer, and Graeme Currie, Chief Development Officer, will host a webcast for investors and analysts today at 15.30 CEST.

The webcast and subsequent Q&A session will be held in English and may be viewed live by registering here: https://forms.office.com/e/aiR9KtDQKL

---

For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager: ole.peter.nordby@lytixbiopharma.com
Optimum Strategic Communications: Jonathan Edwards, Vici Rabbetts: lytix@optimumcomms.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors including PBM Capital, a US based, healthcare-focused investment firm.

Kilde

[drdr]

Thats it baby

[wellsembargo]

Shit.

[drdr]

Hvorfor shit?! Vent til presentasjon kl 15:30!
By the way er Munthe snart ferdig med sin hevnsalg. Gøy å være Lytix aksjonær ut i høst

[vegar_beider]

Det ble mer data.

Fra 7 til 14 (av n=20) pasienter som var kommet så langt i oppfølging at de kan inkluderes i datasettet.

fremdeles 1 partial response og fremdeles 43% disease control.

Så alt i alt holder resultatene seg stabilt på de samme nivåene.

Det ble nevnt og vist til flere pasienter som hadde blitt plassert i PD (progressive disease) kategorien av “tekniske årsaker og av kriterie årsaker” selv om de hadde vist gode resultater, så litt fremsnakking og hinting til at resultatene egentlig var/kunne vært bedre enn det dataene tilsier:

---

case 1:

case 2:

---

De virker godt fornøyde med resultatene så langt selv og legger vekt på at de vil modnes og utvikle seg over tid.
Ellers en god gjennomgang av hvordan behandlingen gjennomføres og hvordan de måler resultater.

---

[TekBot]

Financial calendar

Financial calendar for Lytix Biopharma AS

FINANCIAL YEAR 2023
…

Vis børsmeldingen

09.11.2023 - Quarterly Report - Q3

This information is published pursuant to the requirements set out in the Continuing obligations.

Kilde

[drdr]

Noe endring på top20 før SITC og snart Q3 rapport? Det må komme en melding relatert til SITC!

[TekBot]

Lytix Biopharma: Presentation of third quarter 2023 results, November 9

Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, will release its third quarter 2023 results on Thursday, November 9. The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30 pm CEST.

The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: https://forms.office.com/e/N0xJzSx0Gg
…

Vis børsmeldingen

The presentation will be available at www.lytixbiopharma.com in the Investors section from 08:00 am CET the same day, and a recording of the presentation will after the presentation be made available.

---

For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager: ole.peter.nordby@lytixbiopharma.com

---

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors including PBM Capital, a US based, healthcare-focused investment firm.

Kilde

[wellsembargo]

Du bør skaffe deg innside-abn slik at du kan sjekke dette hver dag selv. Alle som investerer mer enn småpenger kan ha nytte av å tracke dette. Det koster tross alt ikke så mye. Bare meld @pdx så er du i gang

[Hotdog]

Grei stigning på verrica idag ca 10%. Noe nytt på gang hos verrica?

[drdr]

Usikker!
Verrica starter pluss i Nasdaq! Allerede +4%
Noe i gang?

[vegar_beider]

Ikke rart de stiger litt nå
Verrica ser fryktelig underpriset ut og det er ett spennende Q3 de skal presentere 9 November.

Det er første Q hvor de har begynt å selge hovedproduktet sitt.

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third...

[drdr]

Fint at alle stiller spørsmål på Q&A vedrørende klare plan for fremtidige finansiering av selskap! Slik at de forstår at dette er den viktigste tema for investorer som på dette tudspunkt har bremset kursutviklingen!

[TekBot]

Lytix Biopharma presenting at major investor conferences in London and Stockholm in November

Oslo, 8 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Øystein Rekdal, CEO, will deliver oral presentations to institutional investors in London at the LSX Inv€$tival Showcase on the 13th of November, and attend the Jefferies Healthcare Conference on the 14th -16th November.

Investors interested in meeting should get in contact through the event partnering system or through the IR team.
…

Vis børsmeldingen

Later in the month, on the 23rd of November, Dr Rekdal will give a presentation at the Redeye Life Science Day 2023 in Stockholm. There he will answer questions about the Company’s latest positive developments, in particular, the preliminary Phase II data recently presented at ESMO - into the use of LTX-315 for the treatment of advanced melanoma.

The Redeye event can be watched live via the website Redeye Life Science Day 2023 - Redeye and via a recording which will be made available afterwards.

Dr. Rekdal said: “We are looking forward to meeting with international investors at these conferences, to further raise awareness of the progress we have made with our unique approach to overcoming tumor heterogeneity by boosting a broad T-cell response. In particular, I am looking forward to presenting the encouraging preliminary clinical data that we announced at ESMO.”

---

For more information, please contact:
Gjest Breistein, CFO
E-Mail: gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

Kilde

[TekBot]

Lytix Biopharma presents third quarter 2023 results

Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its third quarter 2023 results.

Dr. Øystein Rekdal, Chief Executive Officer of Lytix Biopharma, commented: “We continue our efforts to demonstrate the clinical benefits of LTX-315 in patients with skin cancers. First and foremost, we are satisfied with the encouraging disease control rate achieved in late stage and heavily pretreated melanoma patients in the ATLAS-IT-05 study. Secondly, we recognize the large commercial potential that could be realized through the potential use of LTX-315 in basal cell carcinoma patients. After examining the reassuring data from the Phase II study presented by our partner Verrica Pharmaceuticals during this quarter, we very much look forward to the results of their entire Phase II study, which is expected to be completed during the first half of 2024. Adding to that, we have great expectations for the upcoming study where LTX-315 will be tested in earlier stage melanoma patients in the neoadjuvant NeoLIPA trial at Oslo University Hospital Radiumhospitalet during 2024.”
…

Vis børsmeldingen

Highlights from the third quarter 2023, and post-period events:

• ATLAS-IT-05 – Encouraging preliminary data presented at ESMO 2023:
  o Disease control rate of 43% and one patient achieving a partial response to date
  o There is evidence of tumor shrinkage in both injected and non-injected lesions
• Verrica Pharmaceuticals’ Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (BCC):
  o Complete clearance was observed in lesions treated with the highest dose tested
  o Based on the stronger than expected activity observed in patients receiving LTX-315, Verrica has decided to accelerate the clinical development of LTX-315 and to complete the entire Phase II study in H1 2024
• Neoadjuvant study in earlier stage melanoma patients:
  o An investigator led Phase II study at Oslo University Hospital, Radiumhospitalet is being planned
  o The study protocol was presented at the 15th Nordic Melanoma Meeting, October 12th

Key figures (unaudited):see attached press release

CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein will host a webcast for investors and analysts today at 14.30 CEST. The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: https://forms.office.com/e/N0xJzSx0Gg

The presentation is linked to this press release (and available at https://www.lytixbiopharma.com in the Investors’ section), and a recording of the presentation will be made available after the presentation.

---

For more information, please contact:
Gjest Breistein, CFO
E-Mail: gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

Kilde

[vegar_beider]

Ligger ikke noen link til presentasjonen på hjemmesiden
Var det noen som så på som kan gjengi om det var noe mer enn hva som stod i rapporten? Interssante spørsmål/svar kanskje?

[Falken]

Prøv denne

https://arctic.sharefile.com/share/view/s449cd468dd514eb9a208367f000cde3d

[polygon]

Masse nye spennede data som presenteres der: